This is a working overview of GRF(1-29), written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-12. Anything still debated is marked as such rather than presented as settled.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Despite the first game being finished in 2011, SC and the 3rd were not released until the mid-2010s due to several challenges during the localization process, such as slow communication with Falcom and occupational burnout due to the size of their scripts, with the first game alone having over 1.5 million Japanese characters.
The beginning of his term coincided with the 2022 Central Somalia offensive that recaptured many settlements from Al-Shabaab. Some of these gains would eventually be reversed by the 2025 Shabelle offensive. On 15 May 2026, Mohamud's presidential term officially ended with no election agreement, resulting in a political dispute between state and opposition figures. The 2021–2023 Somali drought was Somalia's most severe drought in 40 years, and affected 7.8 million people. On 30 March 2024, a series of constitutional amendments approved by the Federal Government of Somalia led to disagreements with some federal member states, triggering a political crisis. Three out of six member states withdrew their recognition of the federal government's authority and local clashes erupted in Jubaland and South West State.
Classifying Datura as to its species is difficult, and the descriptions of new species often are accepted prematurely. Later, these "new species" are found to be simply varieties that have evolved due to conditions at a specific location. These new designations usually disappear in a few years. Contributing to the confusion is the fact that various species, such as D. wrightii and D. innoxia, are very similar in appearance, and the variation within a species can be extreme. For example, Datura species can change size of plant, leaf and flowers, all depending on location. The same species, when growing in a half-shady, damp location, can develop into a flowering bush 80 cm (30 in) in height, but when growing in a very dry location, will only grow into a thin plant not much more 13 cm (5 in), with tiny flowers and a few miniature leaves. Datura species are native to dry, temperate and subtropical regions. Most species are native to Mexico, which is considered the centre of origin of the genus. Several species are considered to have extra-American native ranges: D. ferox (native to China), D. metel (native to India and Southeast Asia) and D. leichardthii (native to Australia); however, these may be early introductions from Central America.
==== Distribution ==== The apparent volume of distribution of modafinil is 0.326 to 0.8 L/kg body weight. The plasma protein binding of modafinil is approximately 60%. It is mostly (90%) bound to albumin. Both armodafinil and esmodafinil are substrates of P-glycoprotein, but the clinical significance of this is unknown.
== Concept == Protein nutrition is complex because any proteinogenic amino acid may be the limiting factor in metabolism. Mixing livestock feeds can optimize for growth, or minimize cost while maintaining adequate growth. Similarly, human nutrition is subject to Liebig's law of the minimum: The lowest level of one of the essential amino acids will be the limiting factor in metabolism.
Sources: en.wikipedia.org
=== Helmchen's postulates === Helmchen's postulates are the theoretical models used to predict the elution order and extent of separation of diastereomers (including those formed from CDAs) that are adsorbed onto a surface. Although Helmchen's postulates are specific for amides on silica gel using liquid chromatography, the postulates provide fundamental guidelines for other molecules. Helmchen's Postulates are:
=== 2014: show-cause notices === After sixteen months of investigations, ASADA issued show cause notices to 34 players from Essendon's 2012 player list on 12 June 2014, alleging that they had been administered Thymosin beta-4, having determined that it had sufficient evidence that this was the type of thymosin used in the program. Unlike AOD-9604, it was certain that Thymosin beta-4 was considered banned during the program. ASADA did not allege that the players had used the substances intentionally; rather, the club had knowingly injected the players with the banned substance, and that the players were unaware that it was illegal. The players had ten days to respond, which would be followed by a tribunal hearing in which the burden of proof fell on ASADA to prove that the banned substance was administered to the players. Under the anti-doping codes, players found guilty would receive, as a starting point, a two-year suspension; however, if they were able to demonstrate they were unwittingly given a prohibited substance, they may have been eligible for a 50 per cent reduction. The names of the 34 players were initially suppressed under court order, and were formally released only after the eventual guilty verdict in January 2016. While this was progressing, Essendon performed well under Mark Thompson during the 2014 season, finishing seventh on the ladder and being eliminated in the first week of the finals. Thompson left the club altogether after the season.
Brass bands, flags, banners, parades and monster demonstrations are no different in principle from ecclesiastical processions, cannonades and fire to scare off demons. From Jung's perspective, this replacement of God with the state in a mass society leads to the dislocation of the religious drive and results in the same fanaticism of the church-states of the Dark Ages—wherein the more the state is 'worshipped', the more freedom and morality are suppressed; this ultimately leaves the individual psychically undeveloped with extreme feelings of marginalization.
The two substrates of this enzyme are D-glucose and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are glucono-δ-lactone, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is D-glucose:NADP+ 1-oxidoreductase. Other names in common use include nicotinamide adenine dinucleotide phosphate-linked aldohexose, dehydrogenase, NADP+-linked aldohexose dehydrogenase, NADP+-dependent glucose dehydrogenase, and glucose 1-dehydrogenase (NADP+).
Sources: en.wikipedia.org
Psilocybin mushrooms have been and continue to be used in Indigenous American cultures in religious, divinatory, or spiritual contexts. Reflecting the meaning of the word entheogen ("the god within"), the mushrooms are revered as powerful spiritual sacraments that provide access to sacred worlds. Typically used in small group community settings, they enhance group cohesion and reaffirm traditional values. Terence McKenna documented the worldwide practices of psilocybin mushroom usage as part of a cultural ethos relating to the Earth and mysteries of nature, and suggested that mushrooms enhanced self-awareness and a sense of contact with a "Transcendent Other"—reflecting a deeper understanding of our connectedness with nature. Psychedelic drugs can induce states of consciousness that have lasting personal meaning and spiritual significance in religious or spiritually inclined people; these states are called mystical experiences. Some scholars have proposed that many of the qualities of a drug-induced mystical experience are indistinguishable from mystical experiences achieved through non-drug techniques such as meditation or holotropic breathwork. In the 1960s, Walter Pahnke and colleagues systematically evaluated mystical experiences (which they called "mystical consciousness") by categorizing their common features.
== Mechanism of action == Delta atracotoxin is responsible for the potentially lethal envenomation syndrome seen following funnel-web spider envenomation. d-Atracotoxins induce spontaneous, repetitive firing and prolongation of action potentials resulting in continuous acetylcholine neurotransmitter release from somatic and autonomic nerve endings. This will lead to slower voltage-gated sodium channel inactivation and a hyperpolarizing shift in the voltage-dependence of activation. This action is due to voltage-dependent binding to neurotoxin receptor site-3 in a similar, but not identical, fashion to scorpion a-toxins and sea anemone toxins. In the sea anemone and scorpion toxins, combinations of charged (especially cationic) and hydrophobic side-chains are important for binding to their receptor site (site 3) on the sodium channel. The same applies to delta atracotoxin and versutoxin (a close homologue of delta atracotoxin). Delta atracotoxin presents three distinct charged patches on its surface, as well as a non-polar region centered on the 22-28 loop. Both of these structural features may play a role in its binding to the voltage-gated sodium channel, but further studies are necessary in defining which residues are important for interaction with the sodium channel so that a plausible model can be constructed of its binding site.
{\displaystyle {\begin{aligned}\rho \left({\partial _{t}u_{r}}+u_{r}{\partial _{r}u_{r}}+u_{z}{\partial _{z}u_{r}}\right)&=-{\partial _{r}p}+\mu \left({\frac {1}{r}}\partial _{r}\left(r{\partial _{r}u_{r}}\right)+{\partial _{z}^{2}u_{r}}-{\frac {u_{r}}{r^{2}}}\right)+\rho g_{r}\\\rho \left({\partial _{t}u_{z}}+u_{r}{\partial _{r}u_{z}}+u_{z}{\partial _{z}u_{z}}\right)&=-{\partial _{z}p}+\mu \left({\frac {1}{r}}\partial _{r}\left(r{\partial _{r}u_{z}}\right)+{\partial _{z}^{2}u_{z}}\right)+\rho g_{z}\\{\frac {1}{r}}\partial _{r}\left(ru_{r}\right)+{\partial _{z}u_{z}}&=0.\end{aligned}}}
The M80 Stiletto is an American prototype naval ship using advanced stealth technologies. The M80 was designed by the M Ship Company then built by Knight and Carver, as an experimental testbed ship for The Pentagon’s Office of Force Transformation. It is notable for its innovative pentamaran hull design and advanced carbon fiber composite construction. The multihull uses its width to gain stability. Its five slim hulls create virtually no bow wave, thus obviating the "hull speed' limitation of displacement craft. The Stiletto's "double-M hull" enables the craft to achieve a remarkably steady ride in rough seas at high speed. A disadvantage is that the five hulls give a large "wetted area", increasing drag.
=== Modern pharmacology === For most of the 19th century, drugs were not highly effective, leading Oliver Wendell Holmes Sr. to famously comment in 1842 that "if all medicines in the world were thrown into the sea, it would be all the better for mankind and all the worse for the fishes". During the First World War, Alexis Carrel and Henry Dakin developed the Carrel-Dakin method of treating wounds with an irrigation, Dakin's solution, a germicide which helped prevent gangrene. In the inter-war period, the first anti-bacterial agents such as the sulpha antibiotics were developed. The Second World War saw the introduction of widespread and effective antimicrobial therapy with the development and mass production of penicillin antibiotics, made possible by the pressures of the war and the collaboration of British scientists with the American pharmaceutical industry. Medicines commonly used by the late 1920s included aspirin, codeine, and morphine for pain; digitalis, nitroglycerin, and quinine for heart disorders, and insulin for diabetes. Other drugs included antitoxins, a few biological vaccines, and a few synthetic drugs. In the 1930s, antibiotics emerged: first sulfa drugs, then penicillin and other antibiotics. Drugs increasingly became "the center of medical practice". In the 1950s, other drugs emerged including corticosteroids for inflammation, rauvolfia alkaloids as tranquilizers and antihypertensives, antihistamines for nasal allergies, xanthines for asthma, and typical antipsychotics for psychosis. As of 2007, thousands of approved drugs have been developed.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.